162 related articles for article (PubMed ID: 25270907)
21. Double-hit lymphoma demonstrating t(6;14;18)(p25;q32;q21), suggesting two independent dual-hit translocations, MYC/BCL-2 and IRF4/BCL-2.
Tabata R; Yasumizu R; Tabata C; Kojima M
J Clin Exp Hematop; 2013; 53(2):141-50. PubMed ID: 23995111
[TBL] [Abstract][Full Text] [Related]
22. Molecular-cytogenetic characterization of non-Hodgkin's lymphoma with double and cryptic translocations of the immunoglobulin heavy chain gene.
Kanda-Akano Y; Nomura K; Fujita Y; Horiike S; Nishida K; Nagai M; Miura I; Nakamura S; Seto M; Iida S; Ueda R; Taniwaki M
Leuk Lymphoma; 2004 Aug; 45(8):1559-67. PubMed ID: 15370207
[TBL] [Abstract][Full Text] [Related]
23. LMO2-negative Expression Predicts the Presence of MYC Translocations in Aggressive B-Cell Lymphomas.
Colomo L; Vazquez I; Papaleo N; Espinet B; Ferrer A; Franco C; Comerma L; Hernandez S; Calvo X; Salar A; Climent F; Mate JL; Forcada P; Mozos A; Nonell L; Martinez A; Carrio A; Costa D; Dlouhy I; Salaverria I; Martin-Subero JI; Lopez-Guillermo A; Valera A; Campo E;
Am J Surg Pathol; 2017 Jul; 41(7):877-886. PubMed ID: 28288039
[TBL] [Abstract][Full Text] [Related]
24. Id4 is deregulated by a t(6;14)(p22;q32) chromosomal translocation in a B-cell lineage acute lymphoblastic leukemia.
Bellido M; Aventín A; Lasa A; Estivill C; Carnicer MJ; Pons C; Matías-Guiu X; Bordes R; Baiget M; Sierra J; Nomdedéu JF
Haematologica; 2003 Sep; 88(9):994-1001. PubMed ID: 12969807
[TBL] [Abstract][Full Text] [Related]
25. Tcf-1 promotes genomic instability and T cell transformation in response to aberrant β-catenin activation.
Arnovitz S; Mathur P; Tracy M; Mohsin A; Mondal S; Quandt J; Hernandez KM; Khazaie K; Dose M; Emmanuel AO; Gounari F
Proc Natl Acad Sci U S A; 2022 Aug; 119(32):e2201493119. PubMed ID: 35921443
[TBL] [Abstract][Full Text] [Related]
26. T-cell transcription factor GATA-3 is an immunophenotypic marker of acute leukemias with T-cell differentiation.
Dorfman DM; Morgan EA; Pelton A; Unitt C
Hum Pathol; 2017 Jul; 65():166-174. PubMed ID: 28551327
[TBL] [Abstract][Full Text] [Related]
27. A pediatric B lineage leukemia with coincident MYC and MLL translocations.
Meeker ND; Cherry AM; Bangs CD; Frazer JK
J Pediatr Hematol Oncol; 2011 Mar; 33(2):158-60. PubMed ID: 20829716
[TBL] [Abstract][Full Text] [Related]
28. MYC Expression Is Associated With p53 Expression and TP53 Aberration and Predicts Poor Overall Survival in Acute Lymphoblastic Leukemia/Lymphoma.
Gao L; Harbaugh B; Parr K; Patel P; Golem S; Zhang D; Woodroof J; Cui W
Am J Clin Pathol; 2022 Jan; 157(1):119-129. PubMed ID: 34528662
[TBL] [Abstract][Full Text] [Related]
29. PI3K/mTOR inhibition upregulates NOTCH-MYC signalling leading to an impaired cytotoxic response.
Shepherd C; Banerjee L; Cheung CW; Mansour MR; Jenkinson S; Gale RE; Khwaja A
Leukemia; 2013 Mar; 27(3):650-60. PubMed ID: 23038273
[TBL] [Abstract][Full Text] [Related]
30. Generation of a Tetracycline Regulated Mouse Model of MYC-Induced T-Cell Acute Lymphoblastic Leukemia.
Mahauad-Fernandez WD; Rakhra K; Felsher DW
Methods Mol Biol; 2021; 2318():297-312. PubMed ID: 34019298
[TBL] [Abstract][Full Text] [Related]
31. Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations.
Niitsu N; Okamoto M; Miura I; Hirano M
Leukemia; 2009 Apr; 23(4):777-83. PubMed ID: 19151788
[TBL] [Abstract][Full Text] [Related]
32. [Significance of C-myc expression in T-lymphoblastic lymphoma/leukemia and its relation with prognosis].
Zhang Y; Li J; Xi Y; Bai W; Bai W; Sun R
Zhonghua Bing Li Xue Za Zhi; 2015 Aug; 44(8):571-7. PubMed ID: 26705181
[TBL] [Abstract][Full Text] [Related]
33. Identification of ADGRE5 as discriminating MYC target between Burkitt lymphoma and diffuse large B-cell lymphoma.
Kleo K; Dimitrova L; Oker E; Tomaszewski N; Berg E; Taruttis F; Engelmann JC; Schwarzfischer P; Reinders J; Spang R; Gronwald W; Oefner PJ; Hummel M
BMC Cancer; 2019 Apr; 19(1):322. PubMed ID: 30953469
[TBL] [Abstract][Full Text] [Related]
34. Deep targeted sequencing in pediatric acute lymphoblastic leukemia unveils distinct mutational patterns between genetic subtypes and novel relapse-associated genes.
Lindqvist CM; Lundmark A; Nordlund J; Freyhult E; Ekman D; Carlsson Almlöf J; Raine A; Övernäs E; Abrahamsson J; Frost BM; Grandér D; Heyman M; Palle J; Forestier E; Lönnerholm G; Berglund EC; Syvänen AC
Oncotarget; 2016 Sep; 7(39):64071-64088. PubMed ID: 27590521
[TBL] [Abstract][Full Text] [Related]
35. PRDM16 (1p36) translocations define a distinct entity of myeloid malignancies with poor prognosis but may also occur in lymphoid malignancies.
Duhoux FP; Ameye G; Montano-Almendras CP; Bahloula K; Mozziconacci MJ; Laibe S; Wlodarska I; Michaux L; Talmant P; Richebourg S; Lippert E; Speleman F; Herens C; Struski S; Raynaud S; Auger N; Nadal N; Rack K; Mugneret F; Tigaud I; Lafage M; Taviaux S; Roche-Lestienne C; Latinne D; Libouton JM; Demoulin JB; Poirel HA; ;
Br J Haematol; 2012 Jan; 156(1):76-88. PubMed ID: 22050763
[TBL] [Abstract][Full Text] [Related]
36. Pediatric precursor B-cell acute lymphoblastic leukemia with MYC 8q24 translocation - how to treat?
Zhang C; Amos Burke GA
Leuk Lymphoma; 2018 Aug; 59(8):1807-1813. PubMed ID: 29022749
[TBL] [Abstract][Full Text] [Related]
37. Biology of the lymphomas: cytogenetics, molecular biology, and virology.
Ambinder RF; Griffin CA
Curr Opin Oncol; 1991 Oct; 3(5):806-12. PubMed ID: 1661167
[TBL] [Abstract][Full Text] [Related]
38. Transcriptional deregulation of oncogenic myocyte enhancer factor 2C in T-cell acute lymphoblastic leukemia.
Nagel S; Venturini L; Meyer C; Kaufmann M; Scherr M; Drexler HG; Macleod RA
Leuk Lymphoma; 2011 Feb; 52(2):290-7. PubMed ID: 21261500
[TBL] [Abstract][Full Text] [Related]
39. Extensive molecular mapping of TCRα/δ- and TCRβ-involved chromosomal translocations reveals distinct mechanisms of oncogene activation in T-ALL.
Le Noir S; Ben Abdelali R; Lelorch M; Bergeron J; Sungalee S; Payet-Bornet D; Villarèse P; Petit A; Callens C; Lhermitte L; Baranger L; Radford-Weiss I; Grégoire MJ; Dombret H; Ifrah N; Spicuglia S; Romana S; Soulier J; Nadel B; Macintyre E; Asnafi V
Blood; 2012 Oct; 120(16):3298-309. PubMed ID: 22948044
[TBL] [Abstract][Full Text] [Related]
40. RUNX1 is required for oncogenic
Choi A; Illendula A; Pulikkan JA; Roderick JE; Tesell J; Yu J; Hermance N; Zhu LJ; Castilla LH; Bushweller JH; Kelliher MA
Blood; 2017 Oct; 130(15):1722-1733. PubMed ID: 28790107
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
